JP2019514925A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514925A5 JP2019514925A5 JP2018556411A JP2018556411A JP2019514925A5 JP 2019514925 A5 JP2019514925 A5 JP 2019514925A5 JP 2018556411 A JP2018556411 A JP 2018556411A JP 2018556411 A JP2018556411 A JP 2018556411A JP 2019514925 A5 JP2019514925 A5 JP 2019514925A5
- Authority
- JP
- Japan
- Prior art keywords
- mace
- composition according
- placebo
- compared
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- 239000000902 placebo Substances 0.000 claims 10
- 229940068196 placebo Drugs 0.000 claims 10
- 230000000250 revascularization Effects 0.000 claims 5
- 206010002388 Angina unstable Diseases 0.000 claims 4
- 208000007814 Unstable Angina Diseases 0.000 claims 4
- 230000003111 delayed effect Effects 0.000 claims 4
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 4
- 231100001160 nonlethal Toxicity 0.000 claims 4
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 2
- 230000001934 delay Effects 0.000 claims 2
- 229950011186 semaglutide Drugs 0.000 claims 2
- 108010060325 semaglutide Proteins 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 238000011866 long-term treatment Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16167458.5 | 2016-04-28 | ||
| EP16167458 | 2016-04-28 | ||
| EP16188262.6 | 2016-09-12 | ||
| EP16188262 | 2016-09-12 | ||
| PCT/EP2017/060160 WO2017186896A1 (en) | 2016-04-28 | 2017-04-28 | Semaglutide in cardiovascular conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514925A JP2019514925A (ja) | 2019-06-06 |
| JP2019514925A5 true JP2019514925A5 (enExample) | 2020-06-18 |
| JP7221694B2 JP7221694B2 (ja) | 2023-02-14 |
Family
ID=58668875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018556411A Active JP7221694B2 (ja) | 2016-04-28 | 2017-04-28 | 心血管状態におけるセマグルチド |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20190134162A1 (enExample) |
| EP (1) | EP3448416B1 (enExample) |
| JP (1) | JP7221694B2 (enExample) |
| KR (3) | KR102778218B1 (enExample) |
| CN (1) | CN109069589B (enExample) |
| AU (2) | AU2017256774B2 (enExample) |
| BR (1) | BR112018072020A2 (enExample) |
| CA (1) | CA3022535A1 (enExample) |
| CL (1) | CL2018003045A1 (enExample) |
| DK (1) | DK3448416T3 (enExample) |
| ES (1) | ES2928007T3 (enExample) |
| HR (1) | HRP20221150T1 (enExample) |
| HU (1) | HUE060040T2 (enExample) |
| IL (1) | IL262390B1 (enExample) |
| MA (1) | MA44762A (enExample) |
| MX (1) | MX2018012700A (enExample) |
| MY (1) | MY202967A (enExample) |
| PH (1) | PH12018502274B1 (enExample) |
| PL (1) | PL3448416T3 (enExample) |
| RS (1) | RS63630B1 (enExample) |
| RU (1) | RU2768283C2 (enExample) |
| SI (1) | SI3448416T1 (enExample) |
| WO (1) | WO2017186896A1 (enExample) |
| ZA (2) | ZA202507394B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018012700A (es) * | 2016-04-28 | 2019-01-30 | Novo Nordisk As | Semaglutida en afecciones cardiovasculares. |
| EP3474820B1 (en) | 2017-08-24 | 2024-02-07 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| JP7422754B2 (ja) * | 2018-10-26 | 2024-01-26 | ノヴォ ノルディスク アー／エス | 安定性セマグルチド組成物およびその使用 |
| WO2020127950A1 (en) * | 2018-12-21 | 2020-06-25 | Novo Nordisk A/S | Process of spray drying of glp-1 peptide |
| PE20230819A1 (es) * | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| CN114699510B (zh) * | 2021-12-29 | 2024-07-16 | 浙江湃肽生物有限公司 | 一种司美格鲁肽微针阵列及其制备方法 |
| WO2023238017A1 (en) * | 2022-06-08 | 2023-12-14 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
| CN117462654A (zh) * | 2023-09-28 | 2024-01-30 | 武汉大学人民医院（湖北省人民医院） | 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005535569A (ja) * | 2002-04-04 | 2005-11-24 | ノボ・ノルデイスク・エー／エス | Ｇｌｐ−１アゴニスト及び心臓血管合併症 |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CA2797310C (en) * | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| ES2626013T3 (es) * | 2011-09-06 | 2017-07-21 | Novo Nordisk A/S | Derivados de GLP-1 |
| US9085637B2 (en) * | 2013-11-15 | 2015-07-21 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
| MX2018012700A (es) * | 2016-04-28 | 2019-01-30 | Novo Nordisk As | Semaglutida en afecciones cardiovasculares. |
-
2017
- 2017-04-28 MX MX2018012700A patent/MX2018012700A/es unknown
- 2017-04-28 DK DK17721109.1T patent/DK3448416T3/da active
- 2017-04-28 JP JP2018556411A patent/JP7221694B2/ja active Active
- 2017-04-28 PL PL17721109.1T patent/PL3448416T3/pl unknown
- 2017-04-28 CN CN201780026303.2A patent/CN109069589B/zh active Active
- 2017-04-28 CA CA3022535A patent/CA3022535A1/en active Pending
- 2017-04-28 ES ES17721109T patent/ES2928007T3/es active Active
- 2017-04-28 KR KR1020227036550A patent/KR102778218B1/ko active Active
- 2017-04-28 HR HRP20221150TT patent/HRP20221150T1/hr unknown
- 2017-04-28 KR KR1020257007151A patent/KR20250038818A/ko active Pending
- 2017-04-28 RS RS20220901A patent/RS63630B1/sr unknown
- 2017-04-28 EP EP17721109.1A patent/EP3448416B1/en active Active
- 2017-04-28 US US16/097,032 patent/US20190134162A1/en active Pending
- 2017-04-28 MY MYPI2018703725A patent/MY202967A/en unknown
- 2017-04-28 RU RU2018140900A patent/RU2768283C2/ru active
- 2017-04-28 SI SI201731219T patent/SI3448416T1/sl unknown
- 2017-04-28 KR KR1020187033310A patent/KR20180135012A/ko not_active Ceased
- 2017-04-28 HU HUE17721109A patent/HUE060040T2/hu unknown
- 2017-04-28 BR BR112018072020-8A patent/BR112018072020A2/pt unknown
- 2017-04-28 PH PH1/2018/502274A patent/PH12018502274B1/en unknown
- 2017-04-28 WO PCT/EP2017/060160 patent/WO2017186896A1/en not_active Ceased
- 2017-04-28 MA MA044762A patent/MA44762A/fr unknown
- 2017-04-28 AU AU2017256774A patent/AU2017256774B2/en active Active
-
2018
- 2018-10-15 IL IL262390A patent/IL262390B1/en unknown
- 2018-10-25 CL CL2018003045A patent/CL2018003045A1/es unknown
-
2024
- 2024-10-04 AU AU2024227113A patent/AU2024227113A1/en active Pending
-
2025
- 2025-01-15 US US19/023,039 patent/US20250288649A1/en active Pending
- 2025-05-02 US US19/197,677 patent/US20250262281A1/en active Pending
- 2025-09-03 ZA ZA2025/07394A patent/ZA202507394B/en unknown
- 2025-09-03 ZA ZA2025/07395A patent/ZA202507395B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514925A5 (enExample) | ||
| Abraldes et al. | Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis | |
| RU2018140900A (ru) | Семаглутид при сердечно-сосудистых состояниях | |
| JP2018193377A5 (enExample) | ||
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| HRP20200445T1 (hr) | Metode liječenja ili prevencije tromboze u stentu | |
| HRP20220058T1 (hr) | Sastavi i metode za smanjenje velikih neželjenih kardiovaskularnih događaja | |
| Huddleston et al. | Emerging strategies for treating gout | |
| JP2017529830A5 (enExample) | ||
| MX380070B (es) | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. | |
| JP2016510747A5 (enExample) | ||
| JP2019533715A5 (enExample) | ||
| JP2015531749A5 (enExample) | ||
| JP2020531539A5 (enExample) | ||
| Nelson et al. | Aspirin: latest evidence and developments | |
| WO2007044062A8 (en) | Bile preparations for gastrointestinal disorders | |
| RU2017129068A (ru) | Способ лечения или профилактики атеротромботических явлений у пациентов с инфарктом миокарда в анамнезе | |
| JP2020502134A5 (enExample) | ||
| Lenz et al. | Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke | |
| JP2020531537A5 (enExample) | ||
| JP2020506169A5 (enExample) | ||
| Younis et al. | Antiplatelet drugs overview | |
| WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 | |
| JP2019507174A5 (enExample) | ||
| RU2017114993A (ru) | Твердая фармацевтическая композиция, содержащая амлодипин и лозартан |